Linda West Purchases 45,000 Shares of Context Therapeutics

Linda West, an insider at Context Therapeutics Inc. (NasdaqCM: CNTX), purchased 45,000 shares of the company on June 24, 2026. The transaction was not part of a pre-planned trading program. Shares of Context Therapeutics were trading near $0.56 on Saturday.

Insider Buying and Selling at Context Therapeutics Inc.

Several insiders at Context Therapeutics, including Linda West, bought 45,000 shares each on June 24, 2026. This activity was not under a Rule 10b5-1 plan. Other insiders, such as Karen Smith and Jennifer Evans, also participated in similar transactions. Earlier in the year, on February 19, 2026, Jennifer Lynn Minai-Azary, the Chief Financial Officer, purchased 275,000 shares.

Other Institutional Activity in Context Therapeutics

While some institutions maintained their holdings, others made new moves. Soleus Capital Management, L.P. and Octagon Capital Advisors LP both opened new positions, acquiring 6,963,141 and 5,250,000 shares, respectively. Meanwhile, Blue Owl Capital Holdings LP reduced its stake by 2,343,891 shares, now holding about 5,089,015 shares valued at approximately $13.3 million.

Context Therapeutics Inc. Stock Up 51.2%

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in treatments for solid tumors. With a market cap of about $51.5 million, the company's stock has a 52-week range from $0.55 to $3.62. The stock's 50-day moving average is $2.01, and its 200-day moving average is $1.78. The company has a robust current ratio of 8.95 and a quick ratio of 8.34, with a debt-to-equity ratio of 0.54.

Analysts Set New Price Targets

Several analysts have set their sights on Context Therapeutics. On June 16, 2026, Maxim Group maintained a 'buy' rating with a $4 price target. Piper Sandler also maintains a 'buy' rating with a $7 target. Overall, the analyst consensus is a 'strong buy' with a mean price target of $5.38 based on eight opinions.

About Context Therapeutics

Context Therapeutics Inc., headquartered in Philadelphia, Pennsylvania, is a biotech company focused on developing cancer treatments. Founded in 2015, the company is working on CTIM-76, a product targeting malignant cells through a bispecific antibody approach. The firm collaborates with Integral Molecular, Inc. to advance its cancer therapy pipeline. Led by CEO Martin A. Lehr, Context Therapeutics employs 15 people.

Bottom Line

Insider activity can be a useful indicator of company sentiment, and recent purchases by insiders at Context Therapeutics suggest confidence in its prospects. However, it's important to remember that insider transactions are just one piece of the puzzle. Investors should consider a range of factors, including analyst ratings and market conditions, when evaluating the stock. As always, the data reflects past actions and may not indicate current positions.